Details of Disease

General Information of Disease (ID: DISSACK3)

• Disease Name: Diffuse large B-cell lymphoma
• Synonyms: DLBCL; diffuse large B-cell lymphoma
• Disease Class: 2A81: Diffuse large B-cell lymphoma
• Definition: Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma (NHL) in adults characterized by a median age of presentation in the sixth decade of life (but also rarely occurring in adolescents and children) with the initial presentation being single or multiple rapidly growing masses (that may or may not be painful) in nodal or extranodal sites (such as thyroid, skin, breast, gastrointestinal tract, testes, bone, or brain) and that can be accompanied by symptoms of fever, night sweats and weight loss. DLBCL has an aggressive disease course, with the elderly having a poorer prognosis than younger patients, and with relapses being common.
• Disease Hierarchy:
  DISD8DU7: Aggressive B-cell non-Hodgkin lymphoma
  DISKAXO0: Neoplasm of mature B-cells
  DISSACK3: Diffuse large B-cell lymphoma
• ICD Code:
  ICD-11: ICD-11: 2A81
  ICD-10: ICD-10: C83.3
  ICD-9: ICD-9: 200
  Expand ICD-9: 200
• Disease Identifiers:
  MONDO ID: MONDO_0018905
  MESH ID: D016403
  UMLS CUI: C0079744
  MedGen ID: 86954
  Orphanet ID: 544
  SNOMED CT ID: 109969005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 15 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Axicabtagene ciloleucel	DMYHN59	Approved	CAR T Cell Therapy	[1]
Blinatumomab	DMGECIJ	Approved	Monoclonal antibody	[2]
Durvalumab	DM4PVDY	Approved	Monoclonal antibody	[2]
Epcoritamab	DMEX86V	Approved	Antibody	[3]
Glofitamab	DM45HT6	Approved	Antibody	[4]
Ibrutinib	DMHZCPO	Approved	Small molecular drug	[2]
Loncastuximab tesirine	DMXSVGI	Approved	Antibody drug conjugate	[5]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[2]
Ocrelizumab	DMEZ2KH	Approved	Antibody	[1]
Ofatumumab	DM295PR	Approved	Antibody	[6]
Polatuzumab vedotin	DMF6Y0L	Approved	Antibody	[7]
Tafasitamab	DMPIDFL	Approved	Antibody	[8]
Tazemetostat	DMWP1BH	Approved	Small molecular drug	[2]
Tisagenlecleucel	DMM9BJD	Approved	CAR T Cell Therapy	[2]
Umbralisib	DMYRBO1	Approved	NA	[9]

This Disease is Treated as An Indication in 67 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Abexinostat	DM91LGU	Phase 3	Small molecular drug	[2]
Adcetris	DMEDF2B	Phase 3	NA	[10]
BI-695500	DMT0NTL	Phase 3	NA	[2]
CC-486	DMTNQB0	Phase 3	Small molecular drug	[2]
Enzastaurin	DM5H0R9	Phase 3	Small molecular drug	[2]
GP2013	DMZB45J	Phase 3	NA	[10]
ICP-022	DMU72KL	Phase 3	Small molecular drug	[11]
Pixantrone	DMQGR45	Phase 3	Small molecular drug	[12]
Selinexor	DMBD4K3	Phase 3	Small molecular drug	[13]
Telcyta canfosfamide	DM94IQ3	Phase 3	NA	[14]
VR876	DMLM4S1	Phase 3	NA	[15]
MOR-208	DMDQOWT	Phase 2/3	Antibody	[13]
Zilovertamab vedotin	DM1MZAQ	Phase 2/3	Antibody drug conjugate	[16]
Baltaleucel-T	DM3WCL4	Phase 2	NA	[10]
BI-836826	DMWH7Z5	Phase 2	Antibody	[2]
CART-19	DMHQKN6	Phase 2	CAR T Cell Therapy	[17]
CD19 CAR T cells	DMEK580	Phase 2	CAR T Cell Therapy	[18]
CD20 CAR T cells	DMQGI8R	Phase 2	CAR T Cell Therapy	[18]
Cobomarsen	DMF4MX9	Phase 2	NA	[2]
Coltuximab ravtansine	DMSGFOY	Phase 2	NA	[2]
CTL019	DMMPC6W	Phase 2	CAR T Cell Therapy	[19]
DCDS-4501A	DMQRCX5	Phase 2	Antibody	[20]
DEBIO 1562	DMCNX02	Phase 2	NA	[2]
Denintuzumab mafodotin	DMWQIO3	Phase 2	NA	[2]
DPX Survivac	DMINFHS	Phase 2	Vaccine	[21]
IMO-8400	DMDPNCJ	Phase 2	NA	[13]
INCB50465	DMZJP2T	Phase 2	NA	[2]
ME-401	DMK0UOY	Phase 2	Small molecular drug	[2]
MGCD-0103	DM726HX	Phase 2	Small molecular drug	[13]
MT-3724	DMCNL7Z	Phase 2	Recombinant?protein	[22]
Naratuximab emtansine	DMSWUNX	Phase 2	Antibody	[23]
PF-07901801	DMEVYHR	Phase 2	Fusion protein	[24]
Pidilizumab	DMMO46E	Phase 2	Monoclonal antibody	[25]
Plamotamab	DMOV28A	Phase 2	Bispecific antibody	[26]
PNT-2258	DMUVON0	Phase 2	Antisense drug	[13]
SGN-CD19A	DMS90CU	Phase 2	NA	[27]
TAK-659	DMJH3U0	Phase 2	NA	[2]
Anti-CD19 CAR-T cells	DMDRYZK	Phase 1/2	CAR T Cell Therapy	[28]
Anti-CD19-CAR PBL	DM1WB8H	Phase 1/2	CAR T Cell Therapy	[29]
Anti-CD19-CAR vector-transduced T cells	DMQXU4C	Phase 1/2	CAR T Cell Therapy	[30]
Anti-CD19/22-CAR vector-transduced T cells	DMMUSHR	Phase 1/2	CAR T Cell Therapy	[31]
Anti-CD20 CAR-T cells	DM4WEZL	Phase 1/2	CAR T Cell Therapy	[32]
Anti-CD20-CAR vector-transduced autologous T cells	DMCDUJY	Phase 1/2	CAR T Cell Therapy	[33]
AUTO3	DMC5NSO	Phase 1/2	CAR T Cell Therapy	[34]
Betalutin	DMMNIU4	Phase 1/2	NA	[2]
CD19 CAR T Cells	DMUARWH	Phase 1/2	CAR T Cell Therapy	[35]
CD19.CAR-T cells	DMNZ7F2	Phase 1/2	CAR T Cell Therapy	[36]
CUDC-907	DMHIQDC	Phase 1/2	Small molecular drug	[37]
CX2029	DMYTTBK	Phase 1/2	Antibody drug conjugate	[38]
GEN3013	DMZABYH	Phase 1/2	Antibody	[39]
JCAR014	DMTMVEW	Phase 1/2	CAR T Cell Therapy	[40]
KTE-C19 CAR	DME8JW1	Phase 1/2	NA	[41]
MAK683	DMFK5IX	Phase 1/2	NA	[2]
PCAR-019	DM9DR13	Phase 1/2	CAR T Cell Therapy	[42]
SNS01-T	DM66DIW	Phase 1/2	NA	[43]
AMG 562	DMQ0N5Z	Phase 1	Antibody	[44]
ASP3026	DMW72NJ	Phase 1	Small molecular drug	[45]
CC-122	DM0SRAN	Phase 1	Small molecular drug	[2]
CD19t-haNK	DMT7YOU	Phase 1	CAR-NK Cell therapy	[46]
Human CD19 targeted T Cells	DM0W275	Phase 1	CAR T Cell Therapy	[47]
Iomab-ACT	DMY0QL7	Phase 1	Antibody	[48]
KITE-363	DMIZPF4	Phase 1	CAR-T cell therapy	[49]
LIlotomab satetraxetan	DM2V3UE	Phase 1	NA	[10]
PF-06821497	DML3WT6	Phase 1	Small molecular drug	[50]
Retroviral vector-transduced autologous T cells to express CD22-specific CARs	DMZ8WAQ	Phase 1	CAR T Cell Therapy	[51]
YTB323	DM5BMIO	Phase 1	CAR T Cell Therapy	[52]
Anti-CD19/20-CAR vector-transduced T cells	DM3M9OY	Clinical trial	CAR T Cell Therapy	[53]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DCDT-2980S	DMGM2HY	Discontinued in Phase 2	Antibody	[54]
IM0-8400	DMEF9JW	Discontinued in Phase 1/2	NA	[55]
Dacetuzumab	DMP3X6Q	Terminated	Monoclonal antibody	[56]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
WHI-P154	DMYHWS1	Investigative	Small molecular drug	[57]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761324.
• [4] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761309
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6778).
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [9] ClinicalTrials.gov (NCT02793583) Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL). U.S. National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] ClinicalTrials.gov (NCT04438005) A Study of ICP-022 in Patients With R/R DLBCL (DLBCL). U.S. National Institutes of Health.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7544).
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.Eur J Cancer. 2009 Sep;45(13):2324-32.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040695)
• [16] ClinicalTrials.gov (NCT05139017) A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003). U.S.National Institutes of Health.
• [17] ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
• [18] ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
• [19] ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034127)
• [21] ClinicalTrials.gov (NCT02323230) A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT03488251) PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma. U.S. National Institutes of Health.
• [23] ClinicalTrials.gov (NCT02564744) Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL. U.S. National Institutes of Health.
• [24] ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7692).
• [26] ClinicalTrials.gov (NCT05328102) A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb13676 (Plamotamab) Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. U.S.National Institutes of Health.
• [27] ClinicalTrials.gov (NCT02855359) Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma. U.S. National Institutes of Health.
• [28] ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
• [29] ClinicalTrials.gov (NCT00924326) CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
• [30] ClinicalTrials.gov (NCT01864889) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
• [31] ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
• [32] ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
• [33] ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
• [34] ClinicalTrials.gov (NCT03287817) CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
• [35] ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
• [36] ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
• [37] Clinical pipeline report, company report or official report of Curis.
• [38] ClinicalTrials.gov (NCT03543813) A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029). U.S.National Institutes of Health.
• [39] ClinicalTrials.gov (NCT03625037) GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. U.S. National Institutes of Health.
• [40] ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
• [41] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039436)
• [42] ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
• [43] ClinicalTrials.gov (NCT01435720) Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL). U.S. National Institutes of Health.
• [44] ClinicalTrials.gov (NCT03571828) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma. U.S. National Institutes of Health.
• [45] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7740).
• [46] ClinicalTrials.gov (NCT04052061) QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health.
• [47] ClinicalTrials.gov (NCT03720457) Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
• [48] ClinicalTrials.gov (NCT04512716) Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health.
• [49] ClinicalTrials.gov (NCT04989803) A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma. U.S.National Institutes of Health.
• [50] ClinicalTrials.gov (NCT03460977) PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma. U.S. National Institutes of Health.
• [51] ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
• [52] ClinicalTrials.gov (NCT03960840) CD19-specific CAR-T Cells in CLL/SLL and DLBCL. U.S. National Institutes of Health.
• [53] ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
• [54] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027651)
• [55] Clinical pipeline report, company report or official report of Idera Pharmaceuticals.
• [56] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [57] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [58] Clinical pipeline report, company report or official report of Immunomedics.
• [59] Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 2014 Nov;99(11):1738-45.